BLTE - Belite Bio files for $300M mixed shelf offering
2023-05-22 17:47:48 ET
- Belite Bio ( NASDAQ: BLTE ) has filed for a $300M mixed shelf securities offering.
- The filing does not necessarily indicate that a sale has begun or will occur in the future.
- The company intends to use the proceeds for clinical trials and further clinical development of Tinlarebant, funding research and development of other pipeline products, and for working capital and other general corporate purposes.
- The offering can include American Depository Shares representing ordinary shares, ordinary shares, preferred shares, warrants, overallotment purchase rights, subscription rights, units, capital notes and/or debt securities.
For further details see:
Belite Bio files for $300M mixed shelf offering